|
Market Cap (24-May) $66,720,148 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (16-Jan) 98 (0.00%) (641st) |
|
52w High $0.099 |
52w Low $0.021 |
P/E 25.97 |
EPS 0 |
ACW released this announcement to the ASX on 6 October 2022, 9:33. The announcement is marked as price sensitive, and is 2 page(s) in length and 272.6kb in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.064% short sold according to ASIC data. It was ranked the 529th most shorted stock on the ASX. It remains ranked 641st as of the latest reported data (16 January 2025).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| Trading Halt | 6 October 2022, 9:33 |
| Date of AGM and Closing Date for Director Nominations | 28 September 2022, 8:15 |
| Actinogen AD Biomarkers Context & History Presentation | 13 September 2022, 18:15 |
| Appendix 4G | 25 August 2022, 18:28 |
You must be logged in to post a reply.
Actinogen Medical 